---
figid: PMC7537271__CEI-202-193-g003
figtitle: SARS‐CoV‐2 activates innate immune pathways
organisms:
- NA
pmcid: PMC7537271
filename: CEI-202-193-g003.jpg
figlink: pmc/articles/PMC7537271/figure/cei13523-fig-0003/
number: F3
caption: SARS‐CoV‐2 activates innate immune pathways. SARS‐CoV‐2 infects permissible
  cells via the angiotensin‐converting enzyme 2 (ACE2) and is taken by in the endosome
  where the virus is recognized by Toll‐like receptors 7/9 triggering the myeloid
  differentiation primary response 88 (MyD88) pathway, or Toll‐like receptor (TLR)‐3
  via the TIR‐domain‐containing adapter‐inducing interferon‐β (TRIF) pathway (a).
  Pathogen‐associated molecular patterns (PAMPS) and damage‐associated molecular patterns
  (DAMPS) are also recognized by TLR‐4 (b) or receptor for advanced glycation end
  (RAGE) (d) triggering high mobility group box 1 (HMGB1)‐induced damage and NOD pyrin
  domain‐containing 3 (NLRP3) inflammasome activation. During viral replication ORF3a
  and E proteins form viroporins that augment reactive oxygen species (ROS) production
  and inflammasome activation.
papertitle: 'Innate immunity during SARS‐CoV‐2: evasion strategies and activation
  trigger hypoxia and vascular damage.'
reftext: S. Amor, et al. Clin Exp Immunol. 2020 Nov;202(2):193-209.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8243534
figid_alias: PMC7537271__F3
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC7537271__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7537271__CEI-202-193-g003.html
  '@type': Dataset
  description: SARS‐CoV‐2 activates innate immune pathways. SARS‐CoV‐2 infects permissible
    cells via the angiotensin‐converting enzyme 2 (ACE2) and is taken by in the endosome
    where the virus is recognized by Toll‐like receptors 7/9 triggering the myeloid
    differentiation primary response 88 (MyD88) pathway, or Toll‐like receptor (TLR)‐3
    via the TIR‐domain‐containing adapter‐inducing interferon‐β (TRIF) pathway (a).
    Pathogen‐associated molecular patterns (PAMPS) and damage‐associated molecular
    patterns (DAMPS) are also recognized by TLR‐4 (b) or receptor for advanced glycation
    end (RAGE) (d) triggering high mobility group box 1 (HMGB1)‐induced damage and
    NOD pyrin domain‐containing 3 (NLRP3) inflammasome activation. During viral replication
    ORF3a and E proteins form viroporins that augment reactive oxygen species (ROS)
    production and inflammasome activation.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IFN1@
  - IFNA1
  - IFNA2
  - IFNA17
  - IFNA4
  - IFNA5
  - IFNA6
  - IFNA7
  - IFNA8
  - IFNA10
  - IFNA13
  - IFNA14
  - IFNA16
  - IFNA21
  - TRAF6
  - CHUK
  - IRF7
  - IRF3
  - MYD88
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - TLR7
  - TLR8
  - TBK1
  - TRAF3
  - TLR3
  - TRIM69
  - TICAM1
  - TLR4
  - TRAM1
  - TICAM2
  - TMED7-TICAM2
  - HMGB1
  - AGER
  - MOK
  - CASP1
  - CASP2
  - CASP4
  - CASP5
  - CASP6
  - CASP8
  - CASP9
  - CASP10
  - CASP12
  - CASP14
  - CASP3
  - CASP7
  - IL18
  - NLRP3
  - STS
  - PYCARD
  - TRAM
---
